CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
PLN-74809 +1 moredrug
Likely dose
PLN-74809 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05621252
NCT05621252Phase 2Completed
CompareCT.gov

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Evaluation of PLN-74809 on Type 1 Collagen Deposition Using 68Ga-CBP8 PET/MRI Imaging in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Pliant Therapeutics, Inc.·interventional·Posted Nov 18, 2022·Updated Dec 5, 2025

In Brief

A Phase 2 clinical trial evaluating PLN-74809 and Placebo for Idiopathic Pulmonary Fibrosis. Completed, enrolled 10 participants across 1 site.

Detailed Summary

This is a Phase 2a, single -center, randomized, double-blind, placebo-controlled study to evaluate type 1 collagen deposition in the lungs following once-daily treatment with PLN-74809 for 12-weeks. This study is occurring at Massachusetts General Hospital.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedNov 18, 2022
Enrollment StartJul 13, 2022
Primary CompletionDec 27, 2023
Study CompletionJan 8, 2024
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 3.6 years ago

Interventions

PLN-74809drug

160 mg PLN-74809

Placebodrug

Matching placebo